XCEPTOR LLC - search results

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

receptor miticide/insecticide

Kenya - English - Pharmacy and Poisons Board

zifivax injection

nitron investments limited p.o. box 29014 - 00100, nairobi, kenya - receptor-binding domain (rbd) of sars-cov-2 spike… - injection - receptor-binding domain (rbd) of sars-cov-2 spike… - vaccines

United States - English - NLM (National Library of Medicine)

ibuprofen and famotidine tablet, film coated

ascend laboratories, llc - ibuprofen (unii: wk2xyi10qm) (ibuprofen - unii:wk2xyi10qm), famotidine (unii: 5qzo15j2z8) (famotidine - unii:5qzo15j2z8) - ibuprofen and famotidine tablet, a combination of the nsaid ibuprofen and the histamine h2 -receptor antagonist famotidine, is indicated for the relief of signs and symptoms of rheumatoid arthritis and osteoarthritis and to decrease the risk of developing upper gastrointestinal ulcers, which in the clinical trials was defined as a gastric and/or duodenal ulcer, in patients who are taking ibuprofen for those indications. the clinical trials primarily enrolled patients less than 65 years of age without a prior history of gastrointestinal ulcer. controlled trials do not extend beyond 6 months [see clinical studies (14), use in specific populations (8.5)] . ibuprofen and famotidine tablet is contraindicated in the following patients: - known hypersensitivity (e.g., anaphylactic reactions and serious skin reactions) to ibuprofen or famotidine or any components of the drug product [see warnings and precautions (5.8, 5.11)] . - history of asthma, urticaria, or other allergic-type reactions after taking aspirin or ot

United States - English - NLM (National Library of Medicine)

soliqua 100/33- insulin glargine and lixisenatide injection, solution

sanofi-aventis u.s. llc - insulin glargine (unii: 2zm8cx04rz) (insulin glargine - unii:2zm8cx04rz), lixisenatide (unii: 74o62bb01u) (lixisenatide - unii:74o62bb01u) - insulin glargine 100 u in 1 ml - soliqua 100/33 is a combination of insulin glargine and lixisenatide and is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. limitations of use : - soliqua 100/33 has not been studied in patients with a history of pancreatitis [see warnings and precautions (5.2)] . consider other antidiabetic therapies in patients with a history of pancreatitis. - soliqua 100/33 is not recommended for use in combination with any other product containing a glp-1 receptor agonist [see warnings and precautions (5.5)] . - soliqua 100/33 is not indicated for use in patients with type 1 diabetes mellitus or for the treatment of diabetic ketoacidosis. - soliqua 100/33 has not been studied in patients with gastroparesis and is not recommended in patients with gastroparesis. - soliqua 100/33 has not been studied in combination with prandial insulin. soliqua 100/33 is contraindicated: - during episodes of hypoglycemia [see warnings and precautions (5.6)] . - in patients w